A Conversation with Top 10 Pharma AI LeadershipBuild vs. Buy: Lessons From a Top 10 Pharma on Their AI Journey

One biopharma team spent nearly a year building its own AI solution in-house, then decided what to keep building and where outside help earned its place. Ritu Saxena, PhD, Director of AI Agents at Merck, shares what her team navigated and what they’d do differently. John Wollman, General Manager, Marmot at Komodo Health, adds what he’s learned across the industry about what makes a demo enterprise-ready.

In this on demand webinar, you’ll:

• See exactly where a demo stops being enough, and a high-stakes decision needs more.
• Hear one biopharma team’s real build vs. buy call, made after building in-house for nearly a year.
• Learn what “trustworthy AI” actually requires: grounded, explainable, reproducible, verified, and governed.
• Get unscripted answers from both sides of the table: the builder and the buyer.